Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study

Platelets

Volumn 25, Issue 7, 2014, Pages 517-525

  Storey, Robert F ^a   James, Stefan K ^b   Siegbahn, Agneta ^b   Varenhorst, Christoph ^b   Held, Claes ^b   Ycas, Joseph ^c   Husted, Steen E ^d   Cannon, Christopher P ^e   Becker, Richard C ^f   Steg, Ph Gabriel ^g   Asenblad, Nils ^b   Wallentin, Lars ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Clopidogrel; Coronary artery disease; Platelet aggregation inhibitors; Pneumonia; Sepsis; Ticagrelor

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; INTERLEUKIN 6; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; ASTHMA; BLOOD SAMPLING; CARDIAC PATIENT; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LEUKOCYTE COUNT; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; NEUTROPHIL COUNT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEPSIS; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CORONARY ARTERY DISEASE; MIDDLE AGED; PNEUMONIA; TREATMENT OUTCOME;

ADENOSINE; AGED; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PNEUMONIA; SEPSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84912021475     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.842965     Document Type: Article

References (34)

1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2009;361:1045-1057
2. Van Giezen JJ, Sidaway J, Glaves P, Kirk I, Bjorkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Therapeut 2011;17:164-172
3. Storey RF, Angiolillo D, Patil S, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon C, Becker R, Wallentin L. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO PLATELET Substudy. J Am Coll Cardiol 2010;56:1456-1462
4. Nurden AT. Platelets, inflammation and tissue regeneration. Thrombosis Haemostasis 2011;105(Suppl 1):S13-S33
5. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharmaceut Design 2006;12:1255-1259
6. Evans DJW, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K, Norman KE, Francis SE, Storey RF. The platelet P2Y12 receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009;119:116-122
7. Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-264
8. Guasti L, Dentali F, Castiglioni L, Maroni L, Marino F, Squizzato A, Ageno W, Gianni M, Gaudio G, Grandi AM, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34, 000 subjects. Thrombosis Haemostasis 2011;106:591-599
9. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005;2:29-36
10. James SK, Lindahl B, Timmer JR, Ottervanger JP, Siegbahn A, Stridsberg M, Armstrong P, Califf R, Wallentin L, Simoons ML. Usefulness of biomarkers for predicting long-Term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (A GUSTO IV Substudy). Am J Cardiol 2006;97: 167-172
11. Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P, Kinlay S, for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc 2013;2:E-pub
12. Storey RF, James S, Å senblad N, Siegbahn A, Emanuelsson H, Katus H, Cannon C, Husted S, Steg P, Wallentin L. Consistent benefit of ticagrelor compared to clopidogrel in acute coronary syndrome patients regardless of baseline inflammatory markers. J Am Coll Cardiol 2012;59:E505 (abstract
13. James S, Å kerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene S, Steg PG, Storey RF, Harrington R, et al. Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605
14. Storey RF, Bliden K, Patil SB, Karunakaran A, Ecob R, Butler K, Teng R, Wei C, Tantry US, Gurbel P. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56:185-193
15. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A, et al. Characterisation of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011;32:2945-2953
16. Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: Mechanisms of bacterial-induced platelet activation. J Thrombosis Haemostasis 2011;9:1097-1107
17. Russwurm S, Vickers J, Meier-Hellmann A, Spangenberg P, Bredle D, Reinhart K, Lösche W. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 2002; 17:263-268
18. Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, Claus RA, Bauer M, Lösche W. Anti-platelet drugs and outcome in severe infection: Clinical impact and underlying mechanisms. Platelets 2009;20:50-57
19. Otto GP, Sossdorf M, Boettel J, Kabisch B, Breuel H, Winning J, Lösche W. Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets 2013;24:480-485
20. Seidel M, Winning J, Claus RA, Bauer M, LÖSche W. Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thrombosis Haemostasis 2009;7:1030-1032
21. Winning J, Neumann J, Kohl M, Claus RA, Reinhart K, Bauer M, Lösche W. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Critical Care Med 2010;38:32-37
22. Rahman M, Gustafsson D, Wang Y, Thorlacius H, Braun OO. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets 2013;E-pub July 15
23. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494-502
24. Wiviott S, Braunwald E, McCabe C, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2007;357:2001-2015
25. Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. New Engl J Med 2012;367: 1297-1309
26. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: Randomised placebo-controlled trial. The Lancet 2005;366: 1607-1621
27. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-167
28. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJJ, Jonasson J, Nylander S, Gan L-M. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol 2013;61:723-727
29. Scirica B, Cannon C, Emanuelsson H, Michelson E, Harrington R, Husted S, James S, Katus H, Pais P, Raev D, et al. The incidence of arrhythmias and clinical arrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO trial. J Am Coll Cardiol 2011;57:1908-1916
30. Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by adenosine. Arteriosclerosis, Thrombosis, Vasc Biol 2012;32: 856-864
31. Balamuthusamy S, Arora R. Hematologic adverse effects of clopidogrel. Am J Therapeut 2007;14:106-112
32. Blasco-Colmenares E, Perl TM, Guallar E, Baumgartner W, Conte J, Alejo D, Pastor-Barriuso R, Sharrett A, Faraday N. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med 2009;169:788-795
33. Varenhorst C, Alstrom U, Scirica BM, Hogue CW, Asenblad N, Storey RF, Steg PG, Horrow J, Becker RC, James S, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012;60:1623-1630
34. Gross AK, Dunn SP, Feola DJ, Martin CA, Charnigo R, Li Z, Abdel-Latif A, Smyth SS. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-Analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis 2013;35:147-154